A Case of Hepatocellular Carcinoma with Pulmonary Metastasis Who Showed Complete Response by Cytotoxic Chemotherapy after Sorafenib Failure.
- Author:
Hwa Sun PARK
1
;
Jae Young JANG
;
Min Young BAEK
;
Yong Kwon KIM
;
Hyun Jin YOUN
;
Su Young BACK
;
Soung Won JEONG
;
Sae Hwan LEE
;
Sang Gyune KIM
;
Sang Woo CHA
;
Young Seok KIM
;
Young Deok CHO
;
Hong Soo KIM
;
Boo Sung KIM
Author Information
- Publication Type:Case Report
- Keywords: Hepatocellular carcinoma; Pulmonary metastasis; Cytotoxic chemotherapy; Sorafenib
- MeSH: Carcinoma, Hepatocellular*; Cisplatin; Doxorubicin; Drug Therapy*; Humans; Korea; Middle Aged; Neoplasm Metastasis*; Prognosis
- From:Journal of Liver Cancer 2017;17(1):72-76
- CountryRepublic of Korea
- Language:Korean
- Abstract: Hepatocellular carcinoma (HCC) is the 2nd most common cause of cancer related death in Korea and well-known malignancy with poor prognosis. Sorafenib is the first-line molecular targeted agent in patients with extra-hepatic spread of HCC. However, complete response is extremely rare in patients treated with sorafenib and the disease control rate is only 43%. We report a 53-year-old man with advanced HCC with pulmonary metastasis who showed complete response by cytotoxic chemotherapy with doxorubicin and cisplatin with relatively tolerable adverse effects after failure of treatment with sorafenib.
